Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VIAGRA

« Back to Dashboard
Viagra is a drug marketed by Pfizer Ireland and is included in one NDA. It is available from ten suppliers. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in VIAGRA is sildenafil citrate. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. There are nine tentative approvals for this compound. Additional details are available on the sildenafil citrate profile page.

Summary for Tradename: VIAGRA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list10
2013 Sales:$1,196,812,000

Pharmacology for Tradename: VIAGRA

Clinical Trials for: VIAGRA

Effects of Viagra on Heart Function in Patients With Heart Failure
Status: Completed Condition: Heart Failure; Left Ventricular Dysfunction

Sildenafil for Prevention of Cerebral Vasospasm
Status: Withdrawn Condition: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

Pharmacokinetics of Sildenafil in Premature Infants
Status: Recruiting Condition: Persistent Pulmonary Hypertension of the Newborn

Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Status: Recruiting Condition: Pulmonary Hypertension

Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil
Status: Completed Condition: Healthy

Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels
Status: Completed Condition: Impotence

Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles
Status: Completed Condition: Endometrial Preparation; Frozen Embryo Transfer

A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
Status: Not yet recruiting Condition: Erectile Dysfunction

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Status: Completed Condition: Pulmonary Arterial Hypertention

Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes
Status: Completed Condition: Diabetes Mellitus, Type 2; Endothelial Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-001Mar 27, 1998RXNo6,469,012*PED<disabled>Y<disabled>
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-002Mar 27, 1998RXNo6,469,012*PED<disabled>Y<disabled>
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998RXYes6,469,012*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VIAGRA

Drugname Dosage Strength RLD Submissiondate
sildenafil citrateTablets25 mg and 50 mgViagra11/19/2004
sildenafil citrateTablets100 mgViagra10/25/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc